Biovitrum Wins Phase III Contract

Biovitrum has entered an agreement with Resistentia Pharmaceuticals for process development and manufacturing of the biopharmaceutical substance RES 08 intended for use in Phase III trials of Resistentia’s new protein-based drug candidate for the treatment of allergy.

RES 08 works by blocking the effect of IgE, preventing an allergic reaction and is intended for the treatment of IgE-mediated allergies. Biovitrum’s assignment is to develop the existing process for the biotechnical manufacturing of RES 08 to a standard that meets the demands of a Phase III trial, and furthermore to manufacture sufficient amounts of the substance for the trial. The project will run for more than two years beginning in November 2006.

“We are very pleased with our partnership with the Swedish company Resistentia. This is a complex and extensive assignment which further emphasizes Biovitrum’s role as a leading company in the Nordic biopharma industry,” said Mats Pettersson, president of Biovitrum.

Marcus Bosson, president of Resistentia, said, “Biovitrum’s experience and expertise in the development and manufacturing of Phase III processes is of vital importance at this stage to efficiently advance our project one step closer towards the market.”